INCHEON, South Korea–(BUSINESS WIRE)–#AntigenTestKit—Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.
Celltrion USA will make deliveries to approximately 25,000 U.S. CONUS locations to support military bases, long-term care facilities, community testing sites, critical infrastructure, and other designated places on a weekly basis.
The DLA estimates its order volume to be as much as $626 million considering the change in demand by the COVID-19 community transmission rate in the U.S.
Celltrion believes that this procurement contract underscores Celltrion’s quality, production and supply capabilities as the deal has been awarded after the Department of Defense�s rigorous verification. Celltrion has already proven the quality and safety of DiaTrustTM earlier this year as the product obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on April 16. Celltrions supply capability for the contract volume is sufficiently supported by the large-scale production facility in Korea. In addition, Celltrion USA emphasized the firms drug distribution performance in the US market for the last three years to demonstrate its ability to perform timely deliveries to 25,000 designated places in the U.S., at a competitive price.
Unlike other COVID-19 Antigen Rapid Test kits, DiaTrustTM is a product that applied two antibodies binding COVID-19 virus to both N-protein and S-protein, respectively, resulting in improved sensitivity of 93.3% and specificity of 99.0%. Also, the infection can be diagnosed within only 15 minutes.
The test kits to be supplied through this contact are point-of-care tests (POCT) which can only be used in the presence of medical professionals.
The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrions technology and supply capability. With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrions diagnostic test kits portfolio, said Bonjoong Kim, CEO of Celltrion USA.
About Celltrion, Inc.
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and ECs approval for Inflectra® and Remsima®, respectively, which is the worlds first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and ECs approval for Truxima® and Herzuma®. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines.
Contacts
Celltrion, Inc.
Eunyoung Lee, +82 32 850 4384
Eunyoung.lee1@celltrion.com
HONG KONG SAR - Media OutReach Newswire - 30 May 2024 - Qookka Games is…
—With SEIN Technology, LabVantage LIMS Becomes Industry-First Integrated Platform with EHS Management Solutions for Energy…
Always-on packet capture and real-time multimedia analytics combine to deliver enhanced QoE for voice, video…
DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Prepaid Card and Digital Wallet Business and Investment Opportunities Databook -…
DUBLIN--(BUSINESS WIRE)--The "Taiwan Embedded Finance Business and Investment Opportunities Databook - 75+ KPIs on Embedded…
Hudson Therapeutics’ CEO, Janice Marie McCourt Leads Partnering and Investor Efforts Spotlight on Phase 2B…